Imatinib (Glivec) for Philadelphia positive acute lymphoblastic leukaemia - horizon scanning review
NHSC
Record ID 32005000237
English
Authors' objectives:
This study aims to assess the effectiveness of imatinib (Glivec) for Philadelphia positive acute lymphoblastic leukaemia.
Authors' recommendations:
Imatinib (Glivec) is an oral inhibitor of the Bcr-Abl tyrosine kinase that is in phase III trials for patients in all stages of Philadelphia positive acute lymphoblastic leukaemia (Ph+ALL). Phase II trials have evaluated imatinib monotherapy and combination therapy, before and after stem cell transplantation, in newly diagnosed, relapsed or refractory disease. The only comparative trial evaluating imatinib against multiagent chemotherapy reported increased complete responses with imatinib (92% versus 53%).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Protein-Tyrosine Kinases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.